ASCO 2015 Highlights

Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.
Read Article

Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.
Read Article

Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.
Read Article

CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.
Read Article

Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-KIT gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.
Read Article

Navigation Is About Value
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), said she attended the AVBCC Summit because oncology nurse and patient navigation is "all about value" across the cancer care continuum.
Read Article

Navigators Need a Place at the Table
We are making progress, but oncology nurse navigators need to have a louder voice in these meetings with stakeholders because, as patient advocates, they are often the keepers of patient experience, said Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+).
Read Article

Bringing the Patient Voice to Stakeholders
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), said navigators have "boots on the ground" experiences with patients with cancer, their families, and their caregivers, and oncology navigators are the professionals best suited to deliver these voices to the stakeholders who need to hear them.
Read Article

A Navigator for Every Patient
Every patient with cancer should have a navigator, said Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), and she would like to see AVBCC take a role in realizing this vision.
Read Article

Navigators Have Lessons to Share
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), would like to see everyone with an interest in patient care come to the next AVBCC Summit and learn from navigators how to sustain navigation programs and to learn more about financial navigation.
Read Article

Page 31 of 330